These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37309111)

  • 1. Rapid-Onset Dystonia and Parkinsonism in a Patient With Gaucher Disease.
    Hertz E; Lopez G; Lichtenberg J; Haubenberger D; Tayebi N; Hallett M; Sidransky E
    J Mov Disord; 2023 Sep; 16(3):321-324. PubMed ID: 37309111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A childhood-onset rapid-onset dystonia parkinsonism family with ATP1A3 gene mutation and literatures review].
    Zhang CL; Yin F; He F; Gai N; Shi ZQ; Peng J
    Zhonghua Er Ke Za Zhi; 2017 Apr; 55(4):288-293. PubMed ID: 28441826
    [No Abstract]   [Full Text] [Related]  

  • 3. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene.
    Brashear A; Dobyns WB; de Carvalho Aguiar P; Borg M; Frijns CJ; Gollamudi S; Green A; Guimaraes J; Haake BC; Klein C; Linazasoro G; Münchau A; Raymond D; Riley D; Saunders-Pullman R; Tijssen MA; Webb D; Zaremba J; Bressman SB; Ozelius LJ
    Brain; 2007 Mar; 130(Pt 3):828-35. PubMed ID: 17282997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid-onset dystonia-parkinsonism with ATP1A3 mutation and left lower limb paroxysmal dystonia.
    Nomura S; Kashiwagi M; Tanabe T; Oba C; Yanagi K; Kaname T; Okamoto N; Ashida A
    Brain Dev; 2021 Apr; 43(4):566-570. PubMed ID: 33451880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Expanding Phenotypic Spectrums Associated with ATP1A3 Mutation in a Family with Rapid-Onset Dystonia Parkinsonism.
    Yuan Y; Ran L; Lei L; Zhu H; Zhu X; Chen H
    Neurodegener Dis; 2020; 20(2-3):84-89. PubMed ID: 33326973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal evaluation of olfactory function in individuals with Gaucher disease and
    Lopez GJ; Lichtenberg J; Tayebi N; Ryan E; Lecker AL; Sidransky E
    Front Neurol; 2022; 13():1039214. PubMed ID: 36330429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Blauwendraat C; Tayebi N; Woo EG; Lopez G; Fierro L; Toffoli M; Limbachiya N; Hughes D; Pitz V; Patel D; Vitale D; Koretsky MJ; Hernandez D; Real R; Alcalay RN; Nalls MA; Morris HR; Schapira AHV; Balwani M; Sidransky E
    Mov Disord; 2023 May; 38(5):899-903. PubMed ID: 36869417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of familial juvenile dystonia-parkinsonism: 18F-6-fluorodopa and 18F-fluoro-2-deoxyglucose PET study].
    Hanakawa T; Fukuyama H; Akiguchi I; Kato M; Kimura J; Shibasaki H
    Rinsho Shinkeigaku; 1996 May; 36(5):655-60. PubMed ID: 8905984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of
    Stoker TB; Camacho M; Winder-Rhodes S; Liu G; Scherzer CR; Foltynie T; Evans J; Breen DP; Barker RA; Williams-Gray CH
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):695-702. PubMed ID: 32303560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing.
    Haq IU; Snively BM; Sweadner KJ; Suerken CK; Cook JF; Ozelius LJ; Miller C; McCall WV; Whitlow CT; Brashear A
    Mov Disord; 2019 Oct; 34(10):1528-1536. PubMed ID: 31361359
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Yu L; Peng G; Yuan Y; Tang M; Liu P; Liu X; Ni J; Li Y; Ji C; Fan Z; Zhu W; Luo B; Ke Q
    Front Aging Neurosci; 2022; 14():933893. PubMed ID: 35978945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic innervation topography in GBA-associated de novo Parkinson's disease patients.
    Slingerland S; van der Zee S; Carli G; Slomp AC; Boertien JM; d'Angremont E; Bohnen NI; Albin RL; van Laar T
    Brain; 2024 Mar; 147(3):900-910. PubMed ID: 37748026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocerebrosidase and its relevance to Parkinson disease.
    Do J; McKinney C; Sharma P; Sidransky E
    Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive impairment in rapid-onset dystonia-parkinsonism.
    Cook JF; Hill DF; Snively BM; Boggs N; Suerken CK; Haq I; Stacy M; McCall WV; Ozelius LJ; Sweadner KJ; Brashear A
    Mov Disord; 2014 Mar; 29(3):344-50. PubMed ID: 24436111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.
    Mencacci NE; Isaias IU; Reich MM; Ganos C; Plagnol V; Polke JM; Bras J; Hersheson J; Stamelou M; Pittman AM; Noyce AJ; Mok KY; Opladen T; Kunstmann E; Hodecker S; Münchau A; Volkmann J; Samnick S; Sidle K; Nanji T; Sweeney MG; Houlden H; Batla A; Zecchinelli AL; Pezzoli G; Marotta G; Lees A; Alegria P; Krack P; Cormier-Dequaire F; Lesage S; Brice A; Heutink P; Gasser T; Lubbe SJ; Morris HR; Taba P; Koks S; Majounie E; Raphael Gibbs J; Singleton A; Hardy J; Klebe S; Bhatia KP; Wood NW;
    Brain; 2014 Sep; 137(Pt 9):2480-92. PubMed ID: 24993959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism ATP1A3 mutations reveals functional deficits, which do not correlate with disease severity.
    Lazarov E; Hillebrand M; Schröder S; Ternka K; Hofhuis J; Ohlenbusch A; Barrantes-Freer A; Pardo LA; Fruergaard MU; Nissen P; Brockmann K; Gärtner J; Rosewich H
    Neurobiol Dis; 2020 Sep; 143():105012. PubMed ID: 32653672
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.